The growing grip of limited dominant pharmaceutical corporations is raising significant worries globally. This phenomenon towards domination often contributes to increased drug costs, restricted innovation, and difficulties in receiving critical therapies for people in the world. Analysts contend that more robust regulation is necessary to resolve

India's pharmaceutical landscape presents a complex picture, largely shaped by the considerable influence of a few prominent players. While the sector is often lauded for its generic drug manufacturing capabilities, a closer examination reveals a degree of sector concentration that warrants scrutiny. These traditional companies, including organizat